search
Back to results

The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.

Primary Purpose

Abdominal Obesity

Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Intrathecal Morphine
Intrathecal Morphine + Intravenous Nalbuphine
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Abdominal Obesity

Eligibility Criteria

20 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing abdominoplasty under spinal anesthesia
  • American Society of Anesthesiologists (ASA) class I and II.

Exclusion Criteria:

  • allergy to local anesthetics
  • bleeding diatheses
  • local infection or sepsis

Sites / Locations

  • Assiut University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo group

Nalbuphine group

Arm Description

Outcomes

Primary Outcome Measures

postoperative nausea and vomiting
A verbal descriptive scale (VDS) was used to assess the severity of PONV. ( no nausea=0, severe nausea= 10) by postoperative nausea and vomiting scale which range (o no nasuea to 10 sever vomating). A verbal descriptive scale (VDS) was used to assess the severity of PONV .

Secondary Outcome Measures

postoperative pain and puririts.
Visual analogue scale (VAS) pain scores (no pain = 0, worst possible pain = 10).

Full Information

First Posted
December 19, 2018
Last Updated
March 13, 2020
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT03786562
Brief Title
The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.
Official Title
The Effect of Intravenous Nalbuphine on Postoperative Nausea and Vomiting With Intrathecal Morphine in Abdominoplastic Surgery.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 8, 2019 (Actual)
Primary Completion Date
March 2020 (Anticipated)
Study Completion Date
September 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
How effectively intravenous nalbuphine can reduce the incidence of PONV after intrathecal administration of morphine in abdominoplastic surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Obesity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Title
Nalbuphine group
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Intrathecal Morphine
Intervention Description
Group 1
Intervention Type
Drug
Intervention Name(s)
Intrathecal Morphine + Intravenous Nalbuphine
Intervention Description
Group 2
Primary Outcome Measure Information:
Title
postoperative nausea and vomiting
Description
A verbal descriptive scale (VDS) was used to assess the severity of PONV. ( no nausea=0, severe nausea= 10) by postoperative nausea and vomiting scale which range (o no nasuea to 10 sever vomating). A verbal descriptive scale (VDS) was used to assess the severity of PONV .
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
postoperative pain and puririts.
Description
Visual analogue scale (VAS) pain scores (no pain = 0, worst possible pain = 10).
Time Frame
24 hours

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female undergoing abdominoplasty
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing abdominoplasty under spinal anesthesia American Society of Anesthesiologists (ASA) class I and II. Exclusion Criteria: allergy to local anesthetics bleeding diatheses local infection or sepsis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mohamed Bakri, Prof
Phone
+20882413201
Email
mhbakri@gmail.com
Facility Information:
Facility Name
Assiut University Hospital
City
Assiut
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eman Ismail, A professor

12. IPD Sharing Statement

Learn more about this trial

The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.

We'll reach out to this number within 24 hrs